Biomarkers have their own importance in the process of a therapeutic intervention. It is considered a crucial part of drug discovery, disease detection and finding a cure.
The neurological biomarkers sector is gaining traction in the global market. A new report by Persistence Market Research depicts the progress of the global neurological biomarkers market and the forecast for the upcoming years.
Titled ‘Global Neurological Biomarkers Market-Global Industry Analysis (2012-2016) and Forecast (2017-2025)’, this comprehensive research report projects the overview of the global neurological biomarkers market, which is expected to showcase a significant growth in the coming years, with a compound annual growth rate (CAGR) of 5.1% during the forecast period and reaching a market value of more than $8.7bn by the end of 2025.
Global neurological biomarkers market snapshot
Neurological biomarkers are specific to the detection or analysis of molecular mechanism taking place in a person’s neurological disorder.
Though the market’s scope is restricted to just the neurological segment of a human body, it is expected to hold a large share of the market in the coming years.
This growth is primarily driven by an increase in neurological disorders. There is a huge increase in the rate of the population suffering from disorders such as Alzheimer’s, Parkinson’s, schizophrenia, depression and multiple sclerosis (MS).
The prevalence of such diseases has also triggered drug development practices. Many researchers are solely dedicated to the development of various drugs that are based on the results of biomarkers. Thus, the global neurological biomarkers market is expected to proliferate in the coming years.
The market includes a high application of neurological biomarkers for Alzheimer’s, which is expected to hold the highest market share of more than $2.1bn in the global neurological biomarkers market. However, new application areas such as schizophrenia and spinal muscular atrophy (SMA) are expected to witness more attractiveness in the global market, as both the segments are expected to lead with a growth at a high rate.
The report also reveals growth in the Asia Pacific (APAC) during the forecast period. The region is expected to gain attractiveness in the coming years, as the neurological biomarkers market finds a large area of application and grows at a CAGR of 6.1% during the forecast period.
Global neurological biomarkers market upcoming opportunities and trends
The increasing prevalence of neurodegenerative disorders is expected to support the demand for neurological biomarkers in the global market.
The growth is expected to introduce new trends in the market and help businesses capitalise on opportunities. One such trend is enzyme-linked immunosorbent assay (ELISA), which is a highly sensitive method for detecting proteins in complex matrices such as urine, serum, plasma and saliva. It is considered one of the best available methods for the quantification of proteins, and is also expected to gain traction in the coming years.
The major players behind introducing such trends in the market are also ruling the global neurological biomarkers market. They include Quanterix Corporation, Qiagen, Thermo Fisher Scientific, ADx Neurosciences, Merck, Acobiom, Banyan Biomarkers, Olink, Bio-Rad Laboratories and EuroImmun.
There are many more trends in the market such as mass spectroscopy and integrative biology. The coming years will project a clear picture of the trend that will stand out and lead as a significant driver of global neurological biomarkers market.
To request a sample report, click here.
To find out more information about report methodology, click here.